A new FGFR inhibitor, futibatinib, is approved. Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight.What the heck is GPRC5D (rhymes with CAR-T)?PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900